Radius Pharmaceuticals Expands Abaloparatide Licensing Agreement Globally

Radius Pharmaceuticals, a subsidiary of Radius Health, has announced an expansion of its licensing agreement with Theramex for the commercialization of ELADYNOS® (abaloparatide). This novel bone-forming agent, indicated for osteoporosis treatment in postmenopausal women and men at high risk of fractures, will now be accessible in Mexico, Canada, Israel, South Africa, and Russia. This agreement allows Theramex to explore additional markets for ELADYNOS®.

Under this agreement, Radius will receive upfront and milestone payments, along with tiered royalties. According to Radius CEO Scott Briggs, this expansion aims to enhance treatment accessibility globally. Theramex CEO Rob Stewart expressed enthusiasm about extending their collaboration and reaching more patients worldwide.

Theramex retains its exclusive commercialization rights in Europe, the UK, Australia, and Brazil, where ELADYNOS® has already been launched in select locations.